EMAIL THIS PAGE TO A FRIEND

PloS one

Non-Specific Blocking of miR-17-5p Guide Strand in Triple Negative Breast Cancer Cells by Amplifying Passenger Strand Activity.


PMID 26629823

Abstract

Conventional wisdom holds that only one of the two strands in a micro ribonucleic acid (miRNA) precursor duplex is selected as the active miRNA guide strand. The complementary miRNA passenger strand, however, is thought to be inactive. High levels of the oncogenic miRNA (oncomiR) guide strand called miR-17-5p is overexpressed in triple negative breast cancer (TNBC) and can inhibit ribosomal translation of tumor suppressor gene mRNAs, such as programmed cell death 4 (PDCD4) or phosphatase and tensin homolog (PTEN). We hypothesized that knocking down the oncogenic microRNA (oncomiR) miR-17-5p might restore the expression levels of PDCD4 and PTEN tumor suppressor proteins, illustrating a route to oligonucleotide therapy of TNBC. Contrary to conventional wisdom, antisense knockdown of oncomiR miR-17-5p guide strand reduced PDCD4 and PTEN proteins by 1.8±0.3 fold in human TNBC cells instead of raising them. Bioinformatics analysis and folding energy calculations revealed that mRNA targets of miR-17-5p guide strand, such as PDCD4 and PTEN, could also be regulated by miR-17-3p passenger strand. Due to high sequence homology between the antisense molecules and miR-17-3p passenger strand, as well as the excess binding sites for the passenger strand on the 3'UTR of PDCD4 and PTEN mRNAs, introducing a miR-17-3p DNA-LNA mimic to knock down miR-17-5p reduced PDCD4 and PTEN protein expression instead of raising them. Our results imply that therapeutic antisense sequences against miRNAs should be designed to target the miRNA strand with the greatest number of putative binding sites in the target mRNAs, while minimizing affinity for the minor strand.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2502080
Anti-PDCD4 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2502081
Anti-PDCD4 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1407349
Anti-PDCD4 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA001032
Anti-PDCD4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
P0071 Anti-PDCD4 antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
HPA027214 Anti-PDCD4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB3500256
Anti-PDCD4 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB1410539
Anti-PDCD4 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
B4429
BIS-TRIS, BioPerformance Certified, cell culture tested, suitable for insect cell culture, ≥98.0%
C8H19NO5
B9754
BIS-TRIS, ≥98.0% (titration)
C8H19NO5
RES1161B-A7
BIS-TRIS, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production., suitable for cell culture
C8H19NO5
PHG0004
BIS-TRIS, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, suitable for cell culture
C8H19NO5
B7535
BIS-TRIS, BioXtra, ≥98.0% (titration)
C8H19NO5
14879
BIS-TRIS, BioUltra, ≥99.0% (NT)
C8H19NO5